A Study of Axitinib in Advanced Carcinoid Tumors

Key facts

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Principal Investigator

Jonathan Strosberg, M.D.

H. Lee Moffitt Cancer Center and Research Institute

Intervention

Axitinib(drug)

Enrollment

30 enrolled

Eligibility

18 years · All sexes

Timeline

2011 – 2018

Study locations (2)

• University of California San Francisco (UCSF), San Francisco, California, United States
• H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Collaborators

National Comprehensive Cancer Network · Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Gastroenteric neuroendocrine neoplasm

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07161882
  ALG-LungCancerRegistry (SAFRO2202)
  Société Algérienne de Formation et de Recherche en Oncologie
• ACTIVE NOT RECRUITINGPHASE2NCT03110978
  Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
  M.D. Anderson Cancer Center

See all trials for Gastroenteric neuroendocrine neoplasm →